Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

Partner news

14 Feb 2007
Launch of " Replagal® 3.5 mg "for Anderson-Fabry Disease in Japan

14 Feb 2007 - Dainippon Sumitomo Pharma Co., Ltd.(DSP) announces the upcoming launch on the 15 of February of "Replagal® 3.5 mg" (nonproprietary name: Agalsidase Alfa (Genetic Recombination)) hereafter, Replagal®.

Anderson-Fabry disease is a lysosomal storage disorder caused by congenitally deficient or reduced activity of α-galactosidase-A, a hydrolytic enzyme present in intracellular lysosomes. Anderson-Fabry disease is a multi-system disorder in which, glycosphingolipids, which should normally be broken down, progressively accumulate within cells and tissues as ceramide trihexoside (CTH) resulting in tissue and organ dysfunction, in particular kidney disease, heart disease, and stroke.

Licensed for sale in Japan from Shire Human Genetic Therapies, Inc. (Cambridge, Massachusetts, USA), Replagal® was first approved in the EU in August of 2001 and Japan is the 40th countries where the approval for Replagal® is granted.

Replagal® is characterized by the following features:

1. It is an α-galactosidase-A enzyme preparation produced from human cell cultures through Gene Activation® technology.

2. It reduces accumulation of CTH, the causative agent of Anderson-Fabry disease, through an intravenous infusion of 40 minutes or more once every two weeks.

3. It is expected to reduce pain, caused by Anderson-Fabry disease, that significantly affects patient QOL, and to impede the progression of, and improves, renal and cardiac impairment.

Through this launch of Replagal®, DSP is proud to contribute to the treatment of patients with Anderson-Fabry disease.

(Reference Sheet)

Profile of "Replagal® 3.5 mg"
Brand Name: Replagal® for intravenous infusion 3.5 mg

Nonproprietary Name: Agalsidase alfa (Genetic Recombination)

Dose Form and Strength: Vial preparation, with 3.5 mg Agalsidase alfa (Genetic Recombination) per vial (3.5 mL)

Indication: Anderson-Fabry disease

Dosage and Administration: Generally, Agalsidase alfa (Genetic Recombination) is administered by infusion every other week at a dose of 0.2mg/kg body weight.

Marketing Authorization Holder: Dainippon Sumitomo Pharma Co., Ltd.

Approval Date: October 20, 2006

Date of NHI Price Listing: December 1, 2006

NHI Drug Price Standard: 3.5 mg vial: 357,307 yen per

Package Contents: 1 vial

14 Feb 2007 Launch of " Replagal® 3.5 mg "for Anderson-Fabry Disease in Japan (96KB PDF)

« Back to Partner news

Our global reach

Our products are marketed in over 50 countries worldwide, and we now have offices in 29 countries. View our interactive map, and learn more
about our global reach.

Our locations


Keep up to speed with Shire's latest news by checking out our press release section.

Press releases